Weight-loss pills draw first-time GLP-1 users with lower cost, ease [USA TODAY]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: USA TODAY
Novo's Wegovy pill has been on the market since January, while Lilly's just-approved Foundayo joins the fray this week. Reuters interviews with the specialists show a promising landscape for oral weight-loss drugs as the companies compete for share in the fast-changing obesity treatment market seen topping $100 billion a year in the next decade. Danish drugmaker Novo Nordisk launched injectable Wegovy in 2021. The pill, like injectable Wegovy and Ozempic for diabetes, has the active ingredient semaglutide. In the three months since its approval, the oral version has appealed to patients for its lower cost and ease, the doctors said. The pills don't need refrigeration, are more discreet and don't require the use of needles, said Dr. Christina Nguyen, an obesity and family medicine physician in Atlanta. "One person said I'd rather stay fat than ever use a needle. That's a true fear," she said. Lilly's Foundayo pill, with active ingredient orforglipron, will begin shipping o
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Hims & Hers says limited data stolen in social engineering attack [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk: Downgrading To 'Sell' As GLP-1 Pipeline Faces Many Risks [Seeking Alpha]Seeking Alpha
- Aspect Biosystems receives funding for cellular medicine project [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk CEO says weight-loss drug boom has barely begun [Seeking Alpha]Seeking Alpha
- Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/30/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- NVO's page on the SEC website